Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
HOME > BUSINESS
BUSINESS
- Shonan iPark Launches Local Post in South Korea
March 19, 2024
- ASKA Ties Up with Red Arrow on Novel Preeclampsia Treatment
March 19, 2024
- Canaglu OD Tablet Version Approved in Japan
March 19, 2024
- FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
March 18, 2024
- Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
March 18, 2024
- BIKEN’s 5-in-1 Vaccine Reaches Market Too before NIP Inclusion
March 18, 2024
- Daiichi Sankyo Offers Hefty 7%-Plus Pay Hike in 2024
March 18, 2024
- Bimzelx’s 320 mg Auto-Injector Version Filed in Japan: UCB
March 18, 2024
- Takeda Settles on Lower Pay Hike than 2023; Union Group Says Pharma Labor Talks Tougher than Others
March 15, 2024
- Meiji/KM Biologics’ 5-in-1 Vaccine Now Available Ahead of NIP Rollout
March 15, 2024
- Ono, Sibylla Strike Neuroscience Drug Discovery Pact
March 15, 2024
- Daiichi Sankyo’s TROP2 ADC Now under Review for Breast Cancer in Japan
March 15, 2024
- Chugai Submits Mosunetuzumab for Follicular Lymphoma in Japan
March 15, 2024
- Tecentriq Filed for Alveolar Soft Part Sarcoma in Japan: Chugai
March 15, 2024
- High Demand Triggers Shipment Curb for G-Lasta Biosimilars
March 14, 2024
- Takeda Taps Asuka Miyabashira as New Japan Pharma Chief
March 14, 2024
- Novo Gears Up Sustainability Efforts by Recycling Injectors in Japan
March 13, 2024
- Full Resumption of Quake-Hit Santen Plant Delayed into April
March 13, 2024
- Amgen’s Otezla Hits Primary Goal in PIII of Japanese PPP Patients
March 12, 2024
- Towa Develops Analytical Method for Nitrosamine in Antidepressant Duloxetine
March 12, 2024
ページ
Your reputation as an employer matters.A survey completed by Indeed found that 95% of job seekers found a company’s reputation was an important consideration.When top talent is a scarce commodity, companies need to do more than just make an offer.…
A health ministry panel on pharmaceutical regulations on December 13 discussed the need for confirmatory trial data in Japanese subjects for drugs to treat ultra-rare diseases. The industry proposed waving the implementation of Japanese studies when deemed appropriate in a…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…